Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
2021-006049-36Phase 3Active
- Sponsor
- Incyte
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tafasitamab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Primary endpoint: Overall response rate. Started Apr 2022; status: active.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2021-006049-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006049-36.